
Home » FDA Grants Marketing Clearance to Cepheid’s Xpert Xpress Flu And Xpert Xpress Flu/RSV
FDA Grants Marketing Clearance to Cepheid’s Xpert Xpress Flu And Xpert Xpress Flu/RSV
February 15, 2017
Cepheid has received marketing clearance from the FDA for their Xpert Xpress Flu and Xpert Xpress Flu/RSV.
The built-in redundancy results reduce the impact of seasonal genomic drift in flu viruses that has been a problem with molecular tests.
Both tests deliver results in 20 minutes. — Cynthia Jessup
Upcoming Events
-
26Jan
-
27Jan
-
27Jan
-
09Feb
-
10Feb
-
11Feb